产品
编 号：F741759
分子式：C30H37N9O2S
分子量：587.74
分子式：C30H37N9O2S
分子量：587.74
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2750570-55-7
产品详情
生物活性：
BI-0474 is a potent KRASG12C inhibitor with an IC50 value of 7.0 nM for the GDP-KRAS::SOS1 protein-protein interaction. BI-0474 exhibits good anti-proliferative activity against NCI-H358 cells carrying the G12C mutation. BI-0474 also shows good anti-tumour activity in non-small cell lung cancer xenograft models.
体内研究：
BI-0474 (40 mg/kg; i.p.; single daily for 3 days) shows anti-tumor efficacy and pharmacodynamic biomarker modulation in an NCI-H358 cell line-derived non-small cell lung cancer xenograft model.Animal Model:NMRI nude mice (NCI-H358 cell line-derived non-small cell lung cancer xenograft model).
Dosage:40 mg/kg
Administration:Intraperitoneal administration; single daily for 3 days
Result:Led to induction of programmed cell death in this xenograft model.
体外研究：
BI-0474 (1-10,000 nM; 3 days) shows potent antiproliferative activity of 26 nM on NCI-H358 cells carrying a G12C mutation.
BI-0474 is a potent KRASG12C inhibitor with an IC50 value of 7.0 nM for the GDP-KRAS::SOS1 protein-protein interaction. BI-0474 exhibits good anti-proliferative activity against NCI-H358 cells carrying the G12C mutation. BI-0474 also shows good anti-tumour activity in non-small cell lung cancer xenograft models.
体内研究：
BI-0474 (40 mg/kg; i.p.; single daily for 3 days) shows anti-tumor efficacy and pharmacodynamic biomarker modulation in an NCI-H358 cell line-derived non-small cell lung cancer xenograft model.Animal Model:NMRI nude mice (NCI-H358 cell line-derived non-small cell lung cancer xenograft model).
Dosage:40 mg/kg
Administration:Intraperitoneal administration; single daily for 3 days
Result:Led to induction of programmed cell death in this xenograft model.
体外研究：
BI-0474 (1-10,000 nM; 3 days) shows potent antiproliferative activity of 26 nM on NCI-H358 cells carrying a G12C mutation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备